Kaida BioPharma-West Palm Lunch 6/28/2024

We hope you can join our presentation

Dedicated to advancing ovarian cancer treatment through innovative drug development of specific, targeted small molecules, Kaida BioPharma (KBP) was created from the early foundations and clinical evidence of the discovery and research surrounding G129R, a growth hormone antagonist that binds to the prolactin receptor thus inducing self-induced cell death (autophagy). In gynecologic cancers Prolactin is overexpressed in approximately 80% of the patient population thus making it a primary indicator for cancer tumor development.

The Company successfully validated this and focused its goal on increasing the half-life and delivery in the reformulation of the original molecule which led to the filing of the patent for KBX114 a New Molecular Entity and the partnering with Likarda on delivery. With key research center partners at MD Anderson Cancer Center and Thomas Jefferson Hospital, Kaida BioPharma is taking a new approach to human growth hormone cancer treatment and has actively pursued the open IND filing for G129R in Ovarian Cancer with the FDA. The Company expects to be in the clinic in Q1 2025.

Kaida BioPharma's ultimate goal is to seek FDA approval as a combination therapy and get recognized in all 5 treatment arms for Ovarian and Uterine cancer and be the therapeutic of choice for maintenance therapy.

No matter the market, Cancer is still a major concern that continues to draw investment for a cure. Valuations for Phase 1 Ovarian Cancer Companies range from 280M -1.8B

Presentation Format:

12:00 p.m. to 1:30 p.m. – Presentation and Lunch

Contact:

Raymond Oliver

CEO, Bear Creek Capital

321-439-2120

[email protected]

Host or Publisher Bear Creek Capital